


Provided for non-commercial research and education use.
Not for reproduction, distribution or commercial use.



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/authorsrights>



Contents lists available at ScienceDirect

Cytokine

journal homepage: www.journals.elsevier.com/cytokine

Antimalarial drugs inhibit IFN α -enhanced TNF α and STAT4 expression in monocytes: Implication for systemic lupus erythematosus



Patricia López ^{*}, Javier Rodríguez-Carrio, Ana Suárez

Department of Functional Biology, Immunology Area, Faculty of Medicine, University of Oviedo, Oviedo, Spain

ARTICLE INFO

Article history:

Received 26 March 2013
Received in revised form 19 November 2013
Accepted 2 February 2014
Available online 26 February 2014

Keywords:

IFN α
TNF α
STAT4
Antimalarial therapy
Systemic lupus erythematosus

ABSTRACT

Objectives: To analyse the influence of IFN α on TNF α production by human peripheral blood mononuclear cells (PBMCs), as well as the possible interference of this cytokine on the effect of antimalarial drugs, TNF α regulators widely used in the treatment of systemic lupus erythematosus (SLE).

Methods: PBMCs, monocytes or T cells were treated with IFN α alone or simultaneously to cellular stimuli as well as in the presence or absence of chloroquine. Supernatants from such cultures were collected to quantify TNF α by ELISA. TNF α and STAT4 expression in cultured cells were analysed by intracellular flow cytometry. In addition, STAT4 gene expression and serum levels of TNF α and IFN α were quantified in 53 SLE patients and 45 controls.

Results: IFN α alone did not modify significantly TNF α production, but an increase was observed in stimulated PBMC. Further analyses showed that monocytes were the cellular population responsible for this effect. In addition, IFN α treatment increased STAT4 in stimulated monocytes, suggesting that TNF α upregulation could be mediated by STAT4. On the other hand, the analysis of the antimalarial effect showed that chloroquine was able to inhibit *in vitro* the expression of TNF α and STAT4 enhanced by IFN α . In antimalarial-treated SLE patients, however, only those with high IFN α serum levels presented lower expression of STAT4.

Conclusions: IFN α treatment enhances the induction of TNF α and STAT4 in stimulated monocytes, an effect inhibited *in vitro* by chloroquine treatment. However, the consequence of antimalarial treatment on SLE patients could be different depending on their IFN α serum levels.

© 2014 Elsevier Ltd. All rights reserved.

1. Introduction

Interferon alpha (IFN α) is a cytokine of the type I IFN family with a wide range of effects upon the immune system, including a potent host-protective antiviral response. In fact, IFN α can induce the activation, differentiation and maturation of monocytes into dendritic cells (DCs), increasing the expression of MHC and co-stimulatory molecules [1,2]. In addition, it can produce B cell activation, differentiation and antibody production [3]. These immune-stimulant functions place IFN α in a critical position bridging innate and adaptive immune responses, and suggest that IFN α could be important in the pathogenesis of autoimmunity. The pivotal role of IFN α in the pathogenesis of systemic lupus erythematosus (SLE) and other autoimmune diseases [4] is well

established, since the majority of patients present increased production of type I IFN as well as IFN α -induced genes [5,6]. Moreover, Rönnblom and Alm demonstrated that immunocomplexes containing nucleic acids, characteristic of SLE serum, could trigger the production of high levels of IFN α [7] by plasmacytoid DCs through their interaction with the Toll-like receptor (TLR)-7 and TLR-9 [8,9].

The signal transducer and activator of transcription 4 (STAT4) is one of the gene products involved in the IFN α signaling, and it can be activated and phosphorylated upon ligation of the type I IFN receptor by IFN α in monocytes, macrophages, DCs, and T lymphocytes [10]. Following activation, human STAT4 binds to regulatory regions of several genes to induce proinflammatory cell-mediated immunity [11]. Interestingly, STAT4 variants are associated with susceptibility to SLE [12,13] and the STAT4 risk allele is associated with nephritis and antibodies to double-stranded DNA, two clinical features linked to the severity and activity of the disease [14].

Antimalarial drugs (hydroxychloroquine, chloroquine, and quinacrine) have been used for a long time as disease modifying antirheumatic agents in the treatment of SLE and other

^{*} Corresponding author. Address: Department of Functional Biology, Immunology Area, Faculty of Medicine, C/Julían Clavería s/n, 33006 Oviedo, Spain. Tel.: +34 985102789; fax: +34 985103534.

E-mail addresses: lopezpatricia@uniovi.es (P. López), rodriguezjavier@uniovi.es (J. Rodríguez-Carrio), anasua@uniovi.es (A. Suárez).

autoimmune diseases and they are still widely prescribed. It has been described that antimalarials prevent lupus flares and increase long-term survival of SLE patients [15,16], probably due to their ability to downregulate the production of TNF α and other proinflammatory cytokines, demonstrated *in vitro* by stimulated human monocytes [17–19], and in SLE patients [20,21]. Although the mechanisms for antimalarials are not completely known, it has been described they may block the TLR interaction with nucleic acid ligands by altering lysosomal acidification and disrupting endosomal maturation [22], constituting an interesting therapy for the IFN α blockade, which could prevent the activation of proinflammatory pathways. In fact, it has been previously observed a notable positive correlation between serum levels of IFN α and TNF α [23,24], both cytokines considered essential elements in the etiopathology of the SLE [5,25].

In view of all this evidence, in the present study we investigated the possible involvement of IFN α in the TNF α induction and the STAT4 upregulation, as well as the effect of the antimalarial treatment both *in vitro* and *in vivo*.

2. Material and methods

2.1. Cellular isolation

Human peripheral blood mononuclear cells (PBMCs) were obtained from standard buffy-coat preparations from routine healthy donors (Asturian Blood Transfusion Center, Oviedo, Spain) by centrifugation over Ficoll–Hypaque gradients (Lymphoprep, Nycomed, Norway). Monocytes and T lymphocytes were isolated by means of a Percoll gradient as previously described [2,26]. The monocyte-cell population obtained from the gradient was approximately 85% surface CD14⁺, while T cells were more than 95% CD3⁺, as determined by flow cytometry. Independent experiments were performed with cells from different individuals. All blood donors (the number is specified in each figure legend) were healthy adult volunteers between 18 and 60 years old without any pathology or treatment. Approval for this study was obtained from the Regional Ethics Committee for Clinical Investigation.

2.2. Culture conditions

PBMCs, monocytes and T lymphocytes were incubated at 2×10^6 cells in the presence of phytohemagglutinin (PHA, 2.5 μ g/ml), lipopolysaccharide (LPS, 1 μ g/ml), chloroquine (30 μ M), recombinant human IFN α 2b (Intron-A, 1000 U/ml), or their combinations, in RPMI 1640 medium containing 2 mM L-glutamine and 25 mM Hepes (Bio Whittaker, Belgium) supplemented with 10% heat-inactivated foetal calf serum and the antibiotics streptomycin and ampicillin (100 g/ml) in 24-well flat bottomed plates, at 37 °C in 5% CO₂.

IFN α was obtained from Schering-Plough (Canada) in vials containing 10⁷ International Units (IU) that were dissolved in phosphate-buffered saline (PBS). LPS, PHA and chloroquine was provided by Sigma Chemical Co. (USA) and dissolved in culture medium.

2.3. Cytokine quantification

Culture supernatants and serum samples were collected and maintained at –80 °C until cytokine determination. TNF α levels were determined by an in-house ELISA as previously described [20,23]. IFN α serum levels were quantified by ELISA (PBL Biomedical, USA) following the manufacturer's instructions. This assay has been previously validated in 30 SLE patients and 8 healthy controls by the positive correlations observed between the amount of IFN α

detected in the serum and the expression of IFN α -inducible genes in peripheral blood cells (Supplementary Table 1). The lower limit of detection was 7.5 pg/ml for TNF α and 3.12 pg/ml for IFN α .

2.4. Intracellular expression of TNF α and STAT4

Intracellular accumulation of TNF α and STAT4 was evaluated by flow cytometry in a FACSCanto II flow cytometer (Becton Dickinson, BD Biosciences, CA). PBMCs were cultured in the presence 2 μ M of monensin (Sigma) for the last 8 h. Then, cells were washed and stained with the appropriate monoclonal antibody (MAb) or with the corresponding isotype-matched conjugated irrelevant MAb as a negative control. Extracellular staining of CD14 (Pacific Blue conjugated) was performed for 30 min at 4 °C. After that, cells were fixed/permeabilized (Cytofix/Cytoperm, BD Pharmingen) and intracellularly stained with anti-TNF α (peridinin chlorophyll protein [PerCP]-Cy5.5 conjugated) (eBiosciences Inc., CA) or anti-STAT4 (fluorescein isothiocyanate [FITC] conjugated) (BD Pharmingen) following the manufacturer's instructions. A minimum of 10,000 viable monocytes, gated according to the CD14 expression, were acquired and analyzed using the FACSDiva software 6.1.2 (BD Biosciences). Positive cells for each marker were determined using the corresponding isotype-matched conjugated irrelevant MAbs as negative control. The specific fluorescence intensity was quantified as the mean fluorescence intensity (MFI) calculated by subtracting the background of isotype matched control staining from the total fluorescence.

2.5. STAT4 gene expression

Sample mRNA (poli-A⁺) was isolated from healthy cultured monocytes or whole blood of SLE patients using the mRNA isolation kit for blood/bone marrow (Boehringer Mannheim, USA). Reverse transcription was carried out by standard procedures. Real time reverse transcriptase polymerase chain reaction (RT-PCR) (LightCycler, Roche Diagnostics) was used to quantify STAT4 mRNA by monitoring the fluorescence emitted by SYBR Green I dye, using an external standard (cDNA obtained from LPS stimulated peripheral blood mononuclear cells) to generate a calibration curve. β 2-microglobulin was used as the housekeeping gene, enabling the determination of mRNA relative units. Primers employed were: CACCTGCCACAT TGAGTCAACTA and TAAGACCACCAACGTACGA for STAT4; and CCAGCAGAGAATGGAAAGTC and GATGCTGCTTA CATGTCTCG for β 2-microglobulin.

2.6. SLE patients

All patients included in the study ($n = 53$) were on the Asturian SLE Register [27,28], were all Caucasian in origin, and fulfilled the American College of Rheumatology (ACR) criteria for SLE [29]. Information on clinical features during the disease course was obtained after a detailed review of clinical histories (Table 1). At the time of sampling any patient had flares of disease activity and they were asked precise questions regarding the treatment received over the previous 3 months. Sex and age-matched healthy controls ($n = 45$ (38 women and 7 men); mean age \pm SD: 43.36 \pm 15.74) were enlisted from the Asturian Blood Transfusion Center. Informed consent was obtained from all individuals prior to participation in the study, which was approved by the Regional Ethics Committee for Clinical Investigation.

2.7. Statistical analysis

The Kolmogorov–Smirnov test was used to assess the normal distribution of the data. Data from TNF α and STAT4 *in vitro* expression were represented by mean \pm SD. Differences between culture

Table 1
Demographic and clinical features of SLE patients.

Total SLE patients	53
Sex (female/male) (n)	50/3
Age at diagnosis, years (mean \pm SD)	29.47 \pm 11.60
Disease duration, years (mean \pm SD)	15.19 \pm 11.29
<i>Clinical manifestations, n (%)</i>	
Malar rash	28 (52.8)
Discoid lesions	13 (24.5)
Photosensitivity	30 (56.6)
Oral ulcers	23 (43.4)
Arthritis	43 (81.1)
Serositis	12 (26.6)
Renal disorder	14 (26.4)
Neurological disorder	4 (7.5)
Haematological disorder	31 (58.5)
<i>Autoantibodies, n (%)</i>	
ANAs	53 (100.0)
Anti-dsDNA/titer, U/ml (mean \pm SD)	38 (71.7)/25.11 \pm 42.09
Anti-SSa	22 (41.5)
Anti-SSb	12 (22.6)
Anti-Sm	4 (7.5)
<i>Treatment, n (%)</i>	
None or NSAIDs	10 (18.9)
Antimalarial drugs	29 (54.7)
Glucocorticoids/Dose, mg/day (mean \pm SD)	28 (52.8)/8.14 \pm 6.89
Immunosuppressive drugs ^a	6 (11.3)

dsDNA: double stranded DNA; NSAID: non-steroidal anti-inflammatory drug.

^a Methotrexate, azathioprine, cyclophosphamide, cyclosporine A or mycophenolatemophetil.

conditions in the TNF α production in supernatants were assessed by the Wilcoxon test for paired data, and differences in the TNF α or STAT4 quantification by flow cytometry were tested by paired *T*-test. Non-parametric testing was used to determine differences between patient groups (Mann–Whitney *U*-test) and these data were represented by median (interquartil range). GraphPad Prism 5 software (GraphPad Software) and SPSS 18.0 software package (SPSS Inc.) were used for all determinations and a *p* < 0.05 was considered significant.

3. Theory/calculation

In spite of the proposed cross-regulation between type I IFNs and TNF α under homeostatic conditions, this equilibrium seems to be lost in SLE, since both cytokines are usually increased in these patients and probably involved in the etiopathology of the disease. It is known that antimalarial drugs may downregulate proinflammatory mediators, but only are able to control the disease in several patients. Thus, given the role of STAT4 in the induction of proinflammatory mediators and cell-mediated immunity through IFN α signaling in monocytes, analyzing the influence of IFN α levels and the *in vitro* and *in vivo* effect of antimalarials on STAT4 and TNF α expression should be of interest to detect a biomarker of response to treatment.

4. Results

4.1. IFN α enhances TNF α expression in LPS-stimulated monocytes

To analyse the possible influence of IFN α on the TNF α production, we firstly investigated the possible *in vitro* effect of IFN α on the expression of TNF α by human immune cells. To this end, freshly isolated PBMCs from healthy donors (*n* = 24) were incubated during 48 h with IFN α alone or in combination with LPS or PHA, and supernatants from such cultures were collected for the quantification of TNF α expression. Results suggest a faint effect

on TNF α secretion of the treatment with IFN α alone compared with untreated cells (249.59 \pm 425.15 vs 221.76 \pm 254.15; *n.s.*). However, the presence of IFN α significantly increased TNF α secretion in PBMCs stimulated with PHA (3658.99 \pm 3897.62 vs 3276.32 \pm 3364.36, *p* = 0.03) and with LPS (3247.07 \pm 2844.25 vs 2931.73 \pm 3183.25, *p* = 0.01). Then, we examined separately in monocytes and T cells the effect of IFN α at different times. As expected, IFN α as a single stimulant failed to promote significant production of TNF α in both cell types. However, the presence of IFN α during monocyte stimulation with LPS increased notably TNF α production, detecting a notable cytokine accumulation after 48 h of culture (Fig. 1a). Conversely, IFN α addition to PHA-stimulated T cells only showed a slight increase in TNF α expression (Fig. 1b).

Next, to confirm this effect at the single cell level, we analyzed IFN α induced TNF α production in LPS-stimulated monocytes by intracellular flow cytometry, thus avoiding possible effects of IFN α on monocyte survival. To this end, PBMCs were incubated for 24 h with IFN α alone, or in combination with LPS, and then TNF α expression was analysed in CD14⁺ gated cells (Fig. 1c). In agreement with the previous data, we observed an increase in the amount of TNF α -producer cells in the presence of LPS (untreated: 4.89 \pm 3.34 vs LPS: 19.32 \pm 9.90, *p* = 0.01), that was significantly enhanced in the presence of IFN α (29.78 \pm 15.03, *p* = 0.03), an effect also observed analyzing the MFI (LPS: 117.60 \pm 67.86 vs LPS + IFN α : 184.7 \pm 99.72, *p* = 0.04).

4.2. Chloroquine inhibits IFN α -induced TNF α production and STAT4 expression

It is well known that antimalarial therapy inhibits the production of TNF α and other proinflammatory cytokines [20,21], thus we wanted to determine the influence of these drugs on the production of TNF α induced by IFN α . As is shown in Fig. 2a, chloroquine treatment was able to reduce the TNF α secretion by healthy cultured monocytes in all tested conditions. Also, the analysis of intracellular cytokine accumulation (Fig. 2b) showed that chloroquine inhibits TNF α production by with LPS stimulated monocytes in the presence of IFN α in a similar manner than in the absence of this cytokine (LPS: 117.60 \pm 67.86 vs LPS + CQ: 26.40 \pm 23.04, *p* = 0.01; LPS + IFN α : 184.7 \pm 99.72 vs LPS + IFN α + CQ: 46.05 \pm 20.94, *p* = 0.02).

Next, to determine the possible involvement of STAT4 in the IFN α -induced TNF α production, we analysed STAT4 protein expression in LPS-stimulated monocytes. To this end, cells were cultured in the presence or absence of LPS, IFN α and chloroquine for 24 h and then STAT4 expression was analyzed by intracellular flow cytometry (Fig. 3). As expected, IFN α treatment induced an increase in the expression level of STAT4 by LPS-stimulated monocytes (*p* = 0.03), however, the addition of chloroquine was able to inhibit this IFN α -induced STAT4 expression (LPS: 189.10 \pm 120.00 vs LPS + CQ: 78.88 \pm 34.68, *p* = 0.03; LPS + IFN α : 262.81 \pm 171.60 vs LPS + IFN α + CQ: 96.35 \pm 89.65, *p* = 0.03). Furthermore, this inhibitory effect of chloroquine on the IFN α -induced STAT4 levels in LPS-stimulated monocytes was confirmed at transcriptional level quantifying STAT4 gene expression by real time RT-PCR (LPS + IFN α : 13.92 \pm 5.65 vs LPS + IFN α + CQ: 7.53 \pm 5.66, *p* = 0.01).

4.3. Circulating levels of IFN α affect the STAT4 expression in SLE patients treated with antimalarials

Given the chloroquine ability to inhibit *in vitro* the expression of STAT4 enhanced by IFN α , in an attempt to evaluate this effect *in vivo*, we studied STAT4 gene expression and TNF α serum levels in 53 SLE patients with (*n* = 29) and without (*n* = 24) antimalarial therapy and presenting different IFN α serum levels. As we have previously reported [23], serum levels of IFN α (18.11




Fig. 1. Induction of TNF α secretion by IFN α in monocytes and T cells. Isolated monocytes (a) and T cells (b) were incubated at different times with IFN α alone or at the same time of LPS or PHA stimulation and supernatants from such cultures were collected for the quantification of TNF α production by ELISA. Points represent the median and interquartile range of TNF α (pg/ml) obtained in five independent experiments performed with different blood donors. Intracellular TNF α expression in IFN α -treated monocytes (c). Dot-plots represent the percentage of TNF α -producer CD14⁺ cells after incubation for 24 h with IFN α alone or in combination with LPS. Analysis of the intracellular TNF α accumulation was performed by flow cytometry. A representative experiment was shown.

(45.46) pg/ml) and TNF α (39.24 (116.03) pg/ml) in SLE patients were elevated with respect to controls (IFN α : 5.54 (2.80); TNF α : 19.84 (71.91); pg/ml) and positively correlated in SLE patients ($r=0.291$, $p=0.04$, Spearman's rank correlation test). Thus, patients were classified in IFN α -low and IFN α -high using the percentile 80 obtained in healthy controls ($n=45$) as cut off (P80 = 29.25 pg/ml). In agreement with previous results [20,21], antimalarial treated SLE patients showed strikingly lower levels of TNF α (81.14%) compared to those without such treatment (86.88 (107.03) vs 16.39 (60.94) pg/ml). STAT4 gene expression tends to decrease in patients under antimalarial treatment (64.90 (52.46) vs 57.24 (69.49), n.s.), but, interestingly, the lowest levels, compared to the rest of patients, were observed in IFN α -high antimalarial-treated patients (68.74 (56.05) vs 27.72 (65.95), $p=0.02$), whereas this treatment seems to be ineffective in reducing STAT4 expression in patients with low IFN α serum levels (Fig. 4). This reduction of STAT4 levels was not observed in patients under glucocorticoid or immunosuppressive treatments. Moreover, presence of these drugs in combination with antimalarial therapy did not influence STAT4 levels (Supplementary Table 2).

5. Discussion

During the last few years, the existence of a cross-regulation between type I IFNs and TNF α has been proposed, so that these cytokines can be regarded as opposite vectors in the immune response, remaining balanced under homeostatic conditions but losing equilibrium in specific pathological states, such as autoimmunity. In fact, several *in vitro* and *in vivo* studies showed an inhibitory effect of TNF α on type I IFNs, whereas a reciprocal suppressive effect of IFN α/β on TNF α production has also been suggested. Nevertheless, this counterbalance is controversial in

several autoinflammatory diseases, in which both cytokines may exert a pathological effect.

In this work we observed that IFN α treatment increases TNF α secretion and the number of TNF α -producer cells after *in vitro* monocyte stimulation with LPS. Although several works reported a suppressive effect of type I IFNs in the TNF α production [30–34], other cellular studies suggested that this proposed inhibitory effect may be dependent on both cell type and inflammatory conditions. In this sense, it has been observed that IFN β diminishes *in vitro* TNF α production in T-cell contact-activated monocytes, while the same cytokine enhances TNF α production in LPS-activated monocytes [35]. Moreover, previous exposure to low doses of type I IFNs enhances subsequent response to proinflammatory cytokines such as TNF α by several immune cells [36].

These data are in line with the elevated and directly correlated serum levels of TNF α and IFN α detected in SLE patients that were previously described in a large group [23,24]. Other authors observed that the -308ATNF α allele, associated with an increased production of this cytokine, was positively correlated with higher IFN α serum levels in untreated patients of dermatomyositis at disease onset, suggesting that the relationship between both cytokines could be influenced by the treatment or the disease progression [37]. It has also been described that anti-IFN α monoclonal antibody treatment down-modulated TNF α mRNA expression in peripheral blood and skin lesions in SLE patients [38].

Taking into consideration our results and the published cellular, experimental, and human data, it seems clear that IFN α and TNF α have pleiotropic effects that depend on the time, dosage and cell type, so cross-regulation between both cytokines may occur in physiological conditions, where every cytokine controls another, but is certainly not a universal principle in pathological conditions, such as autoimmunity or inflammation [39]. In fact, if cross-regulation was effective, type I IFN response program might




Fig. 2. Effect of the chloroquine treatment on the IFN α -induced TNF α production. Monocytes cultured for 24 h with IFN α , alone or in combination with LPS, were collected for flow cytometric quantification of intracellular TNF α while supernatants from such cultures were used for TNF α quantification by ELISA. Bars represent mean and SD of TNF α levels in the supernatants of 6 healthy blood donors. Statistical significance between presence/absence of chloroquine in each culture was assessed by Wilcoxon test for paired data ($***p < 0.0001$) (a). Histograms represent the intracellular TNF α expression in a representative donor (shaded) with the respective isotype matched control antibody (black dotted line). Numbers indicate the median fluorescence intensity of TNF α staining with the matched irrelevant control value subtracted (Δ MFI) and percentage of positive cells (% ve) (b).

hamper the elevated TNF α production. However, it is well known that both IFN α and TNF α are over-expressed in many patients with SLE and other autoimmune diseases, sometimes associated with disease activity [40,41]. In such patients, the presence of nucleic acid-containing immune-complexes induces plasmacytoid DCs, and probably other cell types, to produce IFN α [42] after stimulation across TLR-7/9 [9,43]. Similarly, immune-complexes can induce TNF α production [44]. In addition, TNF α may directly stimulate the interferon pathway by inducing IFN β [45].

Antimalarial agents, which have long been used in the treatment of rheumatic diseases, are currently prescribed to SLE patients and they have been associated with a flare reduction and severe disease exacerbations [16,46]. Despite some uncertainty regarding the exact mechanisms underlying their antiinflammatory effects, *in vitro* studies showed that chloroquine interferes with the expression of TNF α and other proinflammatory cytokines [17,19], probably by affecting the cellular lysosomal acidification

[18]. Also, studies in SLE patients showed that antimalarial treatment reduces serum levels of TNF α [20,21], thus suggesting that cytokine inhibition may be involved in a beneficial outcome. Accordingly, our results confirmed that chloroquine treatment inhibits the *in vitro* production of TNF α by healthy LPS-stimulated monocytes, but, in addition, we demonstrated this inhibitory effect even when TNF α induction is enhanced by IFN α , an expected situation in most SLE patients.

Interestingly, lysosomal acidification, an effect of antimalarial agents, is necessary for the TLR activation, so these drugs have been described as antagonists of the TLR7/9 stimulation [47]. Therefore, hydroxychloroquine blocks TLR-mediated activation of pDC *in vitro*, as shown by inhibition of IFN α synthesis, either after induction by immune-complexes [9] or upon stimulation with TLR9 agonists [48,49]. Recently, it has been observed that the significant clinical improvement in SLE patients after hydroxychloroquine therapy correlated with reductions in IFN α levels [50].




Fig. 3. Effect of IFN α and chloroquine on the STAT4 expression in stimulated monocytes. Cells from healthy donors cultured for 24 h in the presence or absence of LPS, IFN α and chloroquine were collected and intracellularly stained for STAT4-FITC expression by flow cytometry. Histograms represent the intracellular STAT4 expression in a donor as example (shaded) with the respective isotype matched control antibody (black dotted line). Numbers indicate the median fluorescence intensity of STAT4 staining with the matched irrelevant control value subtracted (Δ MFI) from one representative experiment ($n = 6$).




Fig. 4. STAT4 gene expression in SLE patients with and without antimalarial treatment and classified by their IFN α serum levels. SLE patients were classified as IFN α -low or IFN α -high using the percentile 80 in healthy controls as cut off. Scatter plots represent STAT4 mRNA relative units from peripheral blood cells of SLE patients with or without antimalarials. Horizontal bars show the median. Statistical significance was assessed by Mann–Whitney U test ($p < 0.05$).

Furthermore, treatment with hydroxychloroquine was associated with an impaired ability of pDCs from subjects with SLE to produce IFN α and TNF α upon stimulation with TLR7/9 agonists [51].

On the other hand, in agreement with the functional relationship between STAT4 and type I IFN receptor signaling, our results showed an upregulation of STAT4 protein expression after IFN α treatment in LPS-stimulated monocytes, in parallel to the increase in the production of TNF α . Since the binding of IFN α to its receptor leads to STAT4 phosphorylation and the subsequent transcription of several IFN α -response proinflammatory molecules in humans [10,11], our results might suggest that the IFN α -induced TNF α secretion by monocytes could be mediated by STAT4. In accordance with this hypothesis, our *in vitro* results revealed, for the first time, that chloroquine treatment was able to reduce STAT4 levels in IFN α and LPS-stimulated monocytes. Actually, IFN α is an inducer of the differentiation and maturation of monocytes into DCs, and it has been suggested that STAT4 expression could

reflect a signal transduction pathway in response to IFN α in this monocyte cellular progression [52].

Finally, to confirm our *in vitro* results, we analyzed the effect of the antimalarial therapy on STAT4 gene expression and TNF α serum levels in SLE patients. As expected, antimalarial treated SLE patients showed strikingly lower levels of TNF α than those without such treatment, but, surprisingly, no significant differences were observed in STAT4 expression. We found, however, that patients under antimalarial treatment and high IFN α levels, showed diminished STAT4 expression, whereas this therapy seemed to be ineffective in reducing STAT4 in patients with low IFN α levels. Thus, STAT4 expression in patients treated with antimalarials depends on the circulating amounts of IFN α , those patients with high levels of IFN α presenting the lowest expression. A possible explanation for the reduced antimalarial-mediated down regulation of STAT4 in the IFN α low group of patients should be related to the presence of certain allelic variants of STAT4 known to constitute a risk factor for SLE and that has been associated with low IFN α serum activity but greater sensitivity to type I IFN signaling in SLE patients [53]. On the other hand, SLE patients with the STAT4 non-risk genotype displayed the commonly observed high IFN α production, which seems to be required for STAT4 downregulation after antimalarial treatment. Therefore, this therapy might be more effective in patients carriers of the wild STAT4 genotype presenting high IFN α levels.

Moreover, gene polymorphisms at the interferon regulatory factor 5 (IRF5), a major mediator of TLR-triggered expression of type I IFN [53] and other proinflammatory cytokines, including TNF α [54], act additionally with STAT4 genotype to increase the risk for SLE [13,55]. This fact could be explained by the functional link between both molecules, since the risk allele of STAT4 determines a higher frequency of anti-dsDNA antibodies in SLE patients, allowing a continued type I IFN stimulation of the STAT4-dependent autoimmune response [13,53].

All these data suggest that antimalarial treatment could be able to reduce STAT4 expression by blocking the interaction between TLR and immune-complexes, thus avoiding the IRF5 action and interfering with IFN α induction. However, in SLE patients with low IFN α production, a feature associated with a low presence of autoantibodies [24] and TNF α [23,56], antimalarial therapy could

be ineffective in reducing STAT4 expression, thus suggesting the use of IFN α as a possible biomarker of the clinical response to antimalarials.

6. Conclusions

The present study showed an enhanced *in vitro* effect of IFN α on the TNF α induction in LPS-activated monocytes from healthy individuals, which could explain the positive correlation observed in SLE patients between both cytokines. This IFN α upregulatory effect was also observed in the levels of STAT4, being both TNF α and STAT4 inhibited when chloroquine was added during stimulation of healthy monocytes. However, results obtained in SLE patients suggest that STAT4 expression is not always decreased during anti-malarial treatment, but depends on the circulating levels of IFN α , which could contribute to an immune activation situation resulting in STAT4 and TNF α induction. Therefore, antimalarial therapy may be especially beneficial to improve SLE pathogenesis in patients with an overactive IFN α pathway, which thus can be blocked.

Acknowledgments

The authors thank SLE patients for its continuous encouragement. This work was supported by the Fondo de Investigación Sanitaria (FIS PI080570) and the Fundación para el Fomento en Asturias de la Investigación Científica Aplicada y la Tecnología (FICYT, IB08-091). J.R.-C. is a recipient of a FPU grant from the Spanish Ministerio de Educación.

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.cyto.2014.02.002>.

References

- [1] Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. *Science* 2001;294:1540–3.
- [2] López P, Gutiérrez C, Suárez A. IFN α treatment generates antigen-presenting cells insensitive to atorvastatin inhibition of MHC-II expression. *Clin Immunol* 2008;129(2):350–9.
- [3] Jégo G, Palucka AK, Blanck J-P, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. *Immunity* 2003;19(2):225–34.
- [4] Rönnblom L. The type I interferon system in the etiopathogenesis of autoimmune diseases. *Ups J Med Sci* 2011;116(4):227–37.
- [5] Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. *Proc Natl Acad Sci USA* 2003;100(5):2610–5.
- [6] Crow MK, Wohlgemuth J. Microarray analysis of gene expression in lupus. *Arthritis Res Ther* 2003;5(6):279–87.
- [7] Rönnblom L, Alm GV. An etiopathogenic role for the type I IFN system in SLE. *Trends Immunol* 2001;22(8):427–31.
- [8] Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. *J Exp Med* 2005;202(8):1131–9.
- [9] Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. *J Clin Invest* 2005;115(2):407–17.
- [10] Tyler DR, Persky ME, Matthews LA, Chan S, Farrar JD. Pre-assembly of STAT4 with the human IFN-alpha/beta receptor-2 subunit is mediated by the STAT4 N-domain. *Mol Immunol* 2007;44(8):1864–72.
- [11] Thieu VT, Yu Q, Chang H-C, Yeh N, Nguyen ET, Sehra S, et al. Signal transducer and activator of transcription 4 is required for the transcription factor T-bet to promote T helper 1 cell-fate determination. *Immunity* 2008;29(5):679–90.
- [12] Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. *N Engl J Med* 2007;357(10):977–86.
- [13] Sigurdsson S, Nordmark G, Garnier S, Grundberg E, Kwan T, Nilsson O, et al. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. *Hum Mol Genet* 2008;17(18):2868–76.
- [14] Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM, Tian C, et al. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. *PLoS Genet* 2008;4(5):e1000084.
- [15] Costedoat-Chalumeau N, Amoura Z, Hulot J-S, Hammoud HA, Aymard G, Cacoub P, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. *Arthritis Rheum* 2006;54(10):3284–90.
- [16] Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. *Ann Rheum Dis* 2010;69(1):20–8.
- [17] Zhu X, Ertel W, Ayala A, Morrison MH, Perrin MM, Chaudry IH. Chloroquine inhibits macrophage tumour necrosis factor-alpha mRNA transcription. *Immunology* 1993;80(1):122–6.
- [18] Weber SM, Levitz SM. Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomal mechanism. *J Immunol* 2000;165(3):1534–40.
- [19] Weber SM, Chen J-M, Levitz SM. Inhibition of mitogen-activated protein kinase signaling by chloroquine. *J Immunol* 2002;168(10):5303–9.
- [20] López P, Gómez J, Mozo L, Gutiérrez C, Suárez A. Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs. *Arthritis Res Ther* 2006;8(2):R42.
- [21] Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. *Lupus* 2006;15(5):268–75.
- [22] Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents: closing the gate on Toll-like receptors? *Arthritis Rheum* 2006;54(10):3068–70.
- [23] López P, Gómez J, Prado C, Gutiérrez C, Suárez A. Influence of functional interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment. *J Rheumatol* 2008;35(8):1559–66.
- [24] Weckerle CE, Imbuka D, Franek BS, Kelly JA, Kumabe M, James JA, et al. Large scale analysis of tumor necrosis factor alpha levels in systemic lupus erythematosus. *Arthritis Rheum* 2012;64:2947–52.
- [25] Aringer M, Feierl E, Steiner G, Stummvoll GH, Höfler E, Steiner CW, et al. Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. *Lupus* 2002;11(2):102–8.
- [26] Seager Danciger J, Lutz M, Hama S, Cruz D, Castrillo A, Lazaro J, et al. Method for large scale isolation, culture and cryopreservation of human monocytes suitable for chemotaxis, cellular adhesion assays, macrophage and dendritic cell differentiation. *J Immunol Methods* 2004;288(1–2):123–34.
- [27] Gómez J, Suárez A, López P, Mozo L, Díaz JB, Gutiérrez C. Systemic lupus erythematosus in Asturias, Spain: clinical and serologic features. *Medicine (Baltimore)* 2006;85(3):157–68.
- [28] López P, Mozo L, Gutiérrez C, Suárez A. Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features. *Lupus* 2003;12(11):860–5.
- [29] Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982;25(11):1271–7.
- [30] Coclet-Ninin J, Dayer JM, Burger D. Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. *Eur Cytokine Network* 1997;8(4):345–9.
- [31] Jungo F, Dayer JM, Modoux C, Hyka N, Burger D. IFN-beta inhibits the ability of T lymphocytes to induce TNF-alpha and IL-1beta production in monocytes upon direct cell-cell contact. *Cytokine* 2001;14(5):272–82.
- [32] Uitdehaag BM, Hoekstra K, Koper JW, Polman CH, Dijkstra CD. IFN-beta1b augments glucocorticoid-induced suppression of tumor necrosis factor-alpha production by increasing the number of glucocorticoid receptors on a human monocytic cell line. *J Interferon Cytokine Res* 2001;21(3):133–5.
- [33] Sauer I, Schaljo B, Vogl C, Gattermeier I, Kolbe T, Müller M, et al. Interferons limit inflammatory responses by induction of tristetraprolin. *Blood* 2006;107(12):4790–7.
- [34] Sharif MN, Susic D, Rothlin CV, Kelly E, Lemke G, Olson EN, et al. Twist mediates suppression of inflammation by type I IFNs and Axl. *J Exp Med* 2006;203(8):1891–901.
- [35] Molnarfi N, Guaz L, Dayer J-M, Burger D. Opposite effects of IFN beta on cytokine homeostasis in LPS- and T cell contact-activated human monocytes. *J Neuroimmunol* 2004;146(1–2):76–83.
- [36] Taniguchi T, Takaoka A. A weak signal for strong responses: interferon-alpha/beta revisited. *Nat Rev Mol Cell Biol* 2001;2(5):378–86.
- [37] Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM. Elevated serum interferon alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after 36 months of therapy. *Arthritis Rheum* 2009;60(6):1815–24.
- [38] Yao Y, Richman L, Higgs BW, Morehouse CA, De los Reyes M, Brohawn P, et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. *Arthritis Rheum* 2009;60(6):1785–96.
- [39] Cantaert T, Baeten D, Tak PP, Van Baarsen LG. Type I IFN and TNF α cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance. *Arthritis Res Ther* 2010;12(5):219.
- [40] Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. *J Exp Med* 2003;197(6):711–23.

- [41] Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. *Br J Rheumatol* 1996;35(11):1067–74.
- [42] Rönnblom L, Alm GV. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. *J Exp Med* 2001;194(12):F59–63.
- [43] Hoshino K, Sugiyama T, Matsumoto M, Tanaka T, Saito M, Hemmi H, et al. IkappaB kinase-alpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9. *Nature* 2006;440(7086):949–53.
- [44] Abrahams VM, Cambridge G, Lydyard PM, Edwards JC. Induction of tumor necrosis factor alpha production by adhered human monocytes: a key role for Fcgamma receptor type IIIa in rheumatoid arthritis. *Arthritis Rheum* 2000;43(3):608–16.
- [45] Yafilina A, Park-Min K-H, Antoniv T, Hu X, Ivashkiv LB. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. *Nat Immunol* 2008;9(4):378–87.
- [46] The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. *N Engl J Med* 1991;324(3):150–4.
- [47] Lövgren T, Eloranta M-L, Kastner B, Wahren-Herlenius M, Alm GV, Rönnblom L. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA. *Arthritis Rheum* 2006;54(6):1917–27.
- [48] Kwok S-K, Lee J-Y, Park S-H, Cho M-L, Min S-Y, Park S-H, et al. Dysfunctional interferon- α production by peripheral plasmacytoid dendritic cells upon Toll-like receptor-9 stimulation in patients with systemic lupus erythematosus. *Arthritis Res Ther* 2008;10(2):R29.
- [49] Martinson JA, Montoya CJ, Usuga X, Ronquillo R, Landay AL, Desai SN. Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. *Antimicrob Agents Chemother* 2010;54(2):871–81.
- [50] Willis R, Seif AM, McGwin G, Martinez-Martinez LA, González EB, Dang N, et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. *Lupus* 2012;21(8):830–5.
- [51] Sacre K, Criswell LA, McCune JM. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. *Arthritis Res Ther* 2012;14(3):R155.
- [52] Frucht DM, Aringer M, Galon J, Danning C, Brown M, Fan S, et al. Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation. *J Immunol* 2000;164(9):4659–64.
- [53] Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN- α in lupus patients in vivo. *J Immunol* 2009;182:34–8.
- [54] Kawai T, Akira S. TLR signaling. *Semin Immunol* 2007;19(1):24–32.
- [55] Abelson A-K, Delgado-Vega AM, Kozyrev SV, Sánchez E, Velázquez-Cruz R, Eriksson N, et al. STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. *Ann Rheum Dis* 2009;68(11):1746–53.
- [56] Weckerle CE, Franek BS, Kelly JA, Kumabe M, Mikolaitis RA, Green SL, et al. Network analysis of associations between serum interferon- α activity, autoantibodies, and clinical features in systemic lupus erythematosus. *Arthritis Rheum* 2011;63(4):1044–53.